Hemoglobinopathies Market Size, Share & Trends Report

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Therapy, By Diagnosis, By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: May, 2019
  • Base Year for Estimate: 2018
  • Report ID: 978-1-68038-736-0
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 100

Industry Insights

The global hemoglobinopathies market size was valued at USD 5.8 billion in 2018 and is expected to expand at a CAGR of 10.2% during the forecast period. Increasing cases of hemoglobinopathies, especially in regions such as Southeast Asia and Africa, is one of the major growth drivers. According to the World Health Organization (WHO), around 300,000 to 500,000 children born each year are affected by hemoglobin disorders. Sickle Cell Disease (SCD) and thalassemia account for more than half of the children born with Hb disorders.

Lack of awareness about these diseases leads to an increase in death to survival ratio for patients suffering from SCD and thalassemia. However, increasing government and company initiatives for spreading awareness pertaining to hemoglobin variant diseases such as the launch of the Cure Sickle Cell Initiative in September 2018 by the National Institutes of Health, is expected to boost market growth over the forecast period.

U.S. hemoglobinopathies market

Universal newborn screening programs particularly in the developed countries are effective measures to facilitate early detection of potentially harmful and fatal disorders, such as thalassemia and SCD in infants. For instance, in 2013, blood disorders division of the Centers for Disease Control and Prevention (CDC) along with the Association of Public Health Laboratories partnered on the hemoglobinopathies project for newborn screening health programs. The project was launched to provide technical assistance to laboratories for assessment of hemoglobinopathies related complications and also imparting education to caregivers, healthcare workers, and patients on the hemoglobinopathy screening programs. 

Increasing R&D activities aimed at developing novel therapeutics are also anticipated to contribute to market growth. The National Heart, Lung, and Blood Institute (NHLBI) which is part of the National Institutes of Health (NIH) funds research programs for SCD to develop new ways to detect and treat the condition and also improve patient outcomes. Using advancements in gene-editing technologies, new procedures are being developed which involves editing or replacing the faulty SCD gene and transplanting the corrected gene back to the patients. An increase in grants for prevention and treatment of SCD through the enactment of laws such as the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act, 2018 is also likely to help in better management of the condition.

Type Insights

The market is segmented into thalassemia (alpha and beta), sickle cell disease, and other hemoglobinopathies such as hereditary elliptocytosis. Gene mutations encoding the globins generate a variety of hereditary conditions producing blood disorders such as thalassemia and SCD.

SCD was the largest segment in terms of revenue in 2018. The segment is also expected to expand at a healthy CAGR over the forecast period, owing to the increasing efforts to improve patient awareness about the disorder and subsequent improvement in diagnosis and treatment.

Diagnosis Insights

Blood testing led the diagnosis segment in terms of revenue in 2018. The fact that blood testing is commonly used as the first-line screening method is a key contributor to its major market share. Genetic testing for the diagnosis of SCD is expected to be the fastest-growing segment over the forecast period due to its efficiency in precise diagnosis and monitoring. Pre-implantation Genetic Diagnosis (PGD) is expected to be the fastest-growing segment for thalassemia diagnosis due to advantages associated with the diagnostic technique such as genetic monitoring during In-Vitro Fertilization (IVF).

Therapy Insights

On the basis of therapy, the market is categorized into blood transfusion, iron chelation therapy, bone marrow transplant, and others. Blood transfusion therapy accounted for the largest share of the market in 2018. The rise in government initiatives for increasing the number of blood donations is a high impact rendering driver for the hemoglobinopathies market.

Global hemoglobinopathies market

A permanent cure for hemoglobinopathies is the biggest requirement. The promising pipeline drugs kept on accelerated review are expected to fulfill the market requirement in the near future. For instance, in July 2018, bluebird bio’s LentiGlobin therapy indicated for use in the treatment of sickle cell disease was granted accelerated assessment by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Regional Insights

North America led the overall market in terms of revenue in 2018 due to rising R&D investments by the key players, better reimbursement scenario, and the presence of high-quality healthcare infrastructure.

Asia Pacific is expected to witness the fastest growth during the forecast period. Introduction of indigenously-manufactured, low-cost diagnostic kits for thalassemia and sickle cell disease coupled with rising patient awareness level is expected to provide manufacturers with lucrative growth opportunities in the near future.

Hemoglobinopathies Market Share Insights

Key market participants include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation.

Key players are focusing on implementing collaboration and licensing deals for sharing technical expertise related to hemoglobinopathies treating therapies. For instance, in January 2014, Sangamo Therapeutics, Inc. and Bioverativ announced a global collaboration agreement that targeted the therapeutics development for hemoglobinopathies.

Hemoglobinopathies Market Report Scope

Report Attribute


Market size value in 2020

USD 7,079.5 million

Revenue forecast in 2026

USD 12.6 billion

Growth Rate

CAGR of 10.2% from 2019 to 2026

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Type, therapy, diagnosis, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K; France; Italy; Spain; Russia; China; Japan; India; South Korea; Australia; Singapore; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; Celgene Corporation

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2026. For the purpose of this study, Grand View Research has segmented the global hemoglobinopathies market report on the basis of type, therapy, diagnosis, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb Variants Diseases

  • Therapy Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb Variants Diseases

  • Diagnosis Outlook (Revenue, USD Million, 2014 - 2026)

    • Thalassemia

      • Alpha Thalassemia

      • Beta Thalassemia

    • Sickle Cell Disease

    • Other Hb variants diseases

  • Regional Outlook (Revenue, USD Million, 2014 - 2026)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities